Showing 4701-4710 of 8671 results for "".
- Can Applying an Electric Field to the Skin Cure Fibrosis?https://practicaldermatology.com/news/can-applying-an-electric-field-to-the-skin-cure-fibrosis/2460965/Applying an electric field to the skin could cure skin fibrosis by reducing overly high collagen levels, a new study suggests. Published in the Journal of Investigative Dermatology, the results open new therapeutic perspectives for the topical treatment of skin fibrosis charact
- Mount Sinai Awarded $4 Million Grant to Launch Skin Biology and Diseases Resource-based Centerhttps://practicaldermatology.com/news/mount-sinai-awarded-4-million-grant-to-launch-skin-biology-and-diseases-resource-based-center/2460963/The Icahn School of Medicine at Mount Sinai is establishing a Skin Biology and Diseases Resource-based Center (SBDRC), funded by a $4 million, five-year P30 grant from the National Institutes of Health and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS).
- Upsher-Smith Introduces Isotretinoin Capsules in UShttps://practicaldermatology.com/news/upsher-smith-introduces-isotretinoin-capsules-in-us/2460960/Isotretinoin capsules AB2-rated to the branded product Absorica® (isotretinoin) are now available in 10mg, 20mg, 30mg, and 40mg strengths from
- FDA Approves Cyltezo as First Interchangeable Biosimilar with Humirahttps://practicaldermatology.com/news/fda-approves-cyltezo-as-first-interchangeable-biosimilar-with-humira/2460957/The FDA approved the supplemental Biologics License Application (sBLA) for Boehringer Ingelheim's Cyltezo (adalimumab-adbm) as the first Interchangeable biosimilar with Humira (adalimumab). The FDA originally approved Cyltezo in 2017 for the treatment of multiple chronic inflammatory diseases
- Allergan Aesthetics Supports Breast Cancer Awareness with New Campaign, Initiativeshttps://practicaldermatology.com/news/allergan-aesthetics-supports-breast-cancer-awareness-with-new-campaign-initiatives/2460954/Allergan Aesthetics’ Power of You campaign is kicking off a new series of initiatives and partnerships to support breast cancer awareness. The Power of You campaign showcases real women and their authentic stories of courage, strength, and community as they embark on their journey
- ASDSA Lauds FDA for Safety Communication on Needle-less Deviceshttps://practicaldermatology.com/news/asdsa-lauds-fda-for-safety-communication-on-needle-less-devices/2460952/The American Society for Dermatologic Surgery Association (ASDSA) applauds the U.S. Food and Drug Administration (FDA) for sending out a safety communication regarding needle-less devices, such as hyaluron pens (HA pens) for injection of dermal fillers. ASDSA had earlier
- Study Highlights Skin Cancer Disparities in Hispanic/Latino Patientshttps://practicaldermatology.com/news/study-highlights-skin-cancer-disparities-in-hispaniclatino-patients/2460950/When Hispanic/Latino people are diagnosed with skin cancer, their tumors are 17 percent larger than tumors in non-Hispanic White patients, a new study shows. For the study, researchers analyzed a total of 3,486 Mohs micrographic surgeries of basal cell, squamous cell, and bas
- Aveeno Launches #SkinVisibility Campaignhttps://practicaldermatology.com/news/aveeno-launches-skinvisibility-campaign/2460948/Aveeno’s new #SkinVisibility campaign aims to address the underdiagnosis, care and treatment of eczema on Black skin. The campaign, which launches during Eczema Awareness Month, underscores the brand's pledge to help 100,000 people with eczema find relief&n
- Safety Concerns Fuel Vaccine Hesitancy in PsO Patients on Biologics, But Data Fail to Show Increased Riskhttps://practicaldermatology.com/news/safety-concerns-fuel-vaccine-hesitancy-in-pso-patients-on-biologics-but-data-fail-to-show-increased-risk/2460947/Safety concerns and concerns about aggravation of their underlying condition are common drivers of COVID-19 vaccine hesitancy among patients with psoriatic disease, results of a new study show. Data come from an analysis of social media posts from patients in the US, UK, France, Germany, and
- Topline Phase 2b Data Promising for Timber's Topical Isotretinoin in CIhttps://practicaldermatology.com/news/topline-phase-2b-data-promising-for-timbers-topical-isotretinoin-in-ci/2460946/Top-line data from Timber Pharmaceuticals’ Phase 2b CONTROL study show “clinically meaningful efficacy with a favorable safety profile” for investigational topical isotretinoin, says the company’s Chairman and CEO John Koconis. TMB-001 is formulated using